ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

1.26
-0.01
(-0.79%)
Closed 22 December 8:00AM
1.26
-0.005
(-0.40%)
After Hours: 10:24AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.26
Bid
1.25
Offer
1.29
Volume
113,249
1.235 Day's Range 1.28
0.87 52 Week Range 22.22
Market Cap
Previous Close
1.27
Open
1.25
Last Trade
2
@
1.2505
Last Trade Time
Financial Volume
US$ 143,147
VWAP
1.264
Average Volume (3m)
521,623
Shares Outstanding
29,878,890
Dividend Yield
-
PE Ratio
-0.58
Earnings Per Share (EPS)
-2.17
Revenue
-
Net Profit
-64.73M

About AN2 Therapeutics Inc

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.27. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 22.22.

AN2 Therapeutics currently has 29,878,890 shares in issue. The market capitalisation of AN2 Therapeutics is US$37.95 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.58.

ANTX Latest News

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-14.86486486491.481.481.231927711.33692174CS
4001.261.6751.234433651.44786354CS
120.218.86792452831.061.6750.9755216231.22945921CS
26-0.75-37.31343283582.013.070.875494381.23969274CS
52-19.02-93.786982248520.2822.220.874325982.50341159CS
156-15.59-92.522255192916.8523.580.871977634.4946569CS
260-15.59-92.522255192916.8523.580.871977634.4946569CS

ANTX - Frequently Asked Questions (FAQ)

What is the current AN2 Therapeutics share price?
The current share price of AN2 Therapeutics is US$ 1.26
How many AN2 Therapeutics shares are in issue?
AN2 Therapeutics has 29,878,890 shares in issue
What is the market cap of AN2 Therapeutics?
The market capitalisation of AN2 Therapeutics is USD 37.95M
What is the 1 year trading range for AN2 Therapeutics share price?
AN2 Therapeutics has traded in the range of US$ 0.87 to US$ 22.22 during the past year
What is the PE ratio of AN2 Therapeutics?
The price to earnings ratio of AN2 Therapeutics is -0.58
What is the reporting currency for AN2 Therapeutics?
AN2 Therapeutics reports financial results in USD
What is the latest annual profit for AN2 Therapeutics?
The latest annual profit of AN2 Therapeutics is USD -64.73M
What is the registered address of AN2 Therapeutics?
The registered address for AN2 Therapeutics is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the AN2 Therapeutics website address?
The website address for AN2 Therapeutics is www.an2therapeutics.com
Which industry sector does AN2 Therapeutics operate in?
AN2 Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

ANTX Discussion

View Posts
glenn1919 glenn1919 1 week ago
ANTX.....................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 2 weeks ago
ANTX........................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 weeks ago
ANTX NEXT WEEK WATCH
πŸ‘οΈ0
stocksrising stocksrising 4 weeks ago
Open market purchase always welcomed :)..even if tiny 😜

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 month ago
ANTX MINI BIO BEAST
👍️ 1
stocksrising stocksrising 1 month ago
I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.
πŸ‘οΈ0
eyeownu eyeownu 1 month ago
NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?
πŸ‘οΈ0
stocksrising stocksrising 1 month ago
Picked up a bit more down here at $1ish, you still in??
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
ANTX under $3
πŸ‘οΈ0
eyeownu eyeownu 5 months ago
looking good
πŸ‘οΈ0
glenn1919 glenn1919 6 months ago
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 9 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 9 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

β€œAN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. β€œPatients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 9 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 9 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
ANTX new 52 week low
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock